{"id":"verorab","safety":{"commonSideEffects":[{"rate":"null","effect":"Pain, redness, swelling, or itching at the injection site"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"groq-llama-8b","explanation":"It works by stimulating the body's immune system to produce antibodies against the rabies virus, providing protection against the disease.","oneSentence":"Verorab is a recombinant rabies vaccine.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T01:40:32.234Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Pre-exposure prophylaxis and post-exposure prophylaxis against rabies"}]},"trialDetails":[{"nctId":"NCT04127786","phase":"PHASE3","title":"Study of Purified Vero Rabies Vaccine Compared With Two Reference Rabies Vaccines, Given in a Pre-exposure Regimen to Children and Adults and as Single Booster Dose to a Subset of Adults","status":"COMPLETED","sponsor":"Sanofi Pasteur, a Sanofi Company","startDate":"2019-10-21","conditions":"Rabies, Healthy Volunteers","enrollment":1708},{"nctId":"NCT07124156","phase":"PHASE1","title":"A Challenge Study to Assess the Blood-stage Efficacy of Full-length SUM-101 Malaria Vaccine Candidate","status":"NOT_YET_RECRUITING","sponsor":"European Vaccine Initiative","startDate":"2026-03-20","conditions":"Malaria Fever","enrollment":24},{"nctId":"NCT06618885","phase":"PHASE1","title":"Safety and Immunogenicity of SUM-101 Malaria Vaccine in Children and Infants Living in Burkina Faso","status":"ACTIVE_NOT_RECRUITING","sponsor":"European Vaccine Initiative","startDate":"2025-08-01","conditions":"Malaria,Falciparum","enrollment":69},{"nctId":"NCT04478084","phase":"PHASE3","title":"Study of Purified Vero Rabies Vaccine Compared With a Reference Rabies Vaccine as Simulated Rabies Post-Exposure Prophylaxis in Adult and Pediatric Population in Thaïland","status":"COMPLETED","sponsor":"Sanofi Pasteur, a Sanofi Company","startDate":"2020-08-04","conditions":"Rabies (Healthy Volunteers)","enrollment":403},{"nctId":"NCT03965962","phase":"PHASE3","title":"Study of Purified Vero Rabies Vaccine Compared With Two Reference Rabies Vaccines in a Simulated Post-Exposure Regimen in Adults","status":"COMPLETED","sponsor":"Sanofi Pasteur, a Sanofi Company","startDate":"2019-07-01","conditions":"Rabies (Healthy Volunteers)","enrollment":640},{"nctId":"NCT07055893","phase":"PHASE3","title":"Immunogenicity and Safety of Rabies Vaccine (Serum-free Vero Cell) in a Simulated Post-exposure Prophylaxis Regimen","status":"NOT_YET_RECRUITING","sponsor":"Sinovac Biotech Co., Ltd","startDate":"2026-03-01","conditions":"Rabies (Healthy Volunteers)","enrollment":390},{"nctId":"NCT07055880","phase":"PHASE2","title":"Immunogenicity and Safety of Different Dosages of Rabies Vaccine (Serum-free Vero Cell)","status":"NOT_YET_RECRUITING","sponsor":"Sinovac Biotech Co., Ltd","startDate":"2025-07-28","conditions":"Rabies","enrollment":120},{"nctId":"NCT07055295","phase":"PHASE3","title":"Immunogenicity and Safety of Rabies Vaccine (Serum-free Vero Cell) in a Pre-exposure Prophylaxis Regimen","status":"NOT_YET_RECRUITING","sponsor":"Sinovac Biotech Co., Ltd","startDate":"2026-03-01","conditions":"Rabies","enrollment":390},{"nctId":"NCT01622062","phase":"PHASE3","title":"Immunogenicity and Safety of Verorab® in a \"One-week\" Intradermal Post-exposure Prophylaxis Regimen","status":"COMPLETED","sponsor":"Sanofi Pasteur, a Sanofi Company","startDate":"2012-06-29","conditions":"Rabies","enrollment":600},{"nctId":"NCT03700242","phase":"PHASE3","title":"Imovax® Rabies and VERORAB® Immunogenicity and Safety After One Week 2-sites Intradermal or 1-site Intramuscular Pre-Exposure Prophylaxis Regimens, Followed by a Simulated Post-Exposure Prophylaxis Regimen at One Year","status":"COMPLETED","sponsor":"Sanofi Pasteur, a Sanofi Company","startDate":"2018-09-26","conditions":"Healthy Volunteers (Rabies Immunization)","enrollment":570},{"nctId":"NCT00842530","phase":"PHASE2","title":"Efficacy and Safety of Dengue Vaccine in Healthy Children","status":"COMPLETED","sponsor":"Sanofi Pasteur, a Sanofi Company","startDate":"2009-02","conditions":"Dengue Virus, Dengue Fever, Dengue Hemorrhagic Fever","enrollment":4002},{"nctId":"NCT01983553","phase":"","title":"Long-Term Study of Hospitalized Dengue & Safety in Thai Children Included in a Tetravalent Dengue Vaccine Efficacy Study","status":"COMPLETED","sponsor":"Sanofi Pasteur, a Sanofi Company","startDate":"2013-09-10","conditions":"Dengue, Dengue Fever, Dengue Hemorrhagic Fever","enrollment":3203},{"nctId":"NCT02490956","phase":"PHASE4","title":"Diagnostic Immunization With Rabies Vaccine in Patients With PID","status":"UNKNOWN","sponsor":"Chulalongkorn University","startDate":"2015-04","conditions":"Primary Immunodeficiency","enrollment":40},{"nctId":"NCT01228383","phase":"PHASE2","title":"Rabies Virus Neutralizing Activity and Safety of CL184, a Monoclonal Antibody Cocktail, in Simulated Rabies Post-Exposure Prophylaxis in Healthy Adults","status":"COMPLETED","sponsor":"Crucell Holland BV","startDate":"2011-12","conditions":"Rabies","enrollment":240}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":45,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_3","status":"active","brandName":"Verorab®","genericName":"Verorab®","companyName":"Sinovac Biotech Co., Ltd","companyId":"sinovac-biotech-co-ltd","modality":"Biologic","firstApprovalDate":"","aiSummary":"Verorab is a recombinant rabies vaccine. Used for Pre-exposure prophylaxis and post-exposure prophylaxis against rabies.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}